SEC Company Response from Forte Biosciences, Inc. (FBRX) (CIK 0001419041) (FBRX) — May 21, 2018
Forte Biosciences, Inc. (FBRX) (CIK 0001419041)
Date: May 21, 2018 · CIK: 0001419041 · Accession: 0001193125-18-169516
AI Filing Summary & Sentiment
File numbers found in text: 333-224880
Letter
Tocagen Inc.
3030 Bunker Hill Street
Suite 230
San Diego, CA 92109
(858) 412-8400
May 21, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christine Westbrook
Re: Tocagen Inc.
Registration Statement on Form S-3
Filed: May 11, 2018
File No. 333-224880
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tocagen Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on Wednesday, May 23, 2018, or as soon thereafter as is practicable.
In connection with this request, the Registrant hereby acknowledges that:
•
should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please contact Karen E. Anderson of Cooley LLP at (858) 550-6088.
Sincerely,
TOCAGEN INC.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Tocagen Inc.
3030 Bunker Hill Street
Suite 230
San Diego, CA 92109
(858) 412-8400
May 21, 2018
VIA EDGAR
United States
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christine Westbrook
Re:
Tocagen Inc.
Registration Statement on Form
S-3
Filed: May 11, 2018
File No. 333-224880
Ladies and Gentlemen:
Pursuant to Rule 461 under the
Securities Act of 1933, as amended, Tocagen Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced
Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on Wednesday, May 23, 2018, or as soon thereafter as is practicable.
In connection with this request, the Registrant hereby acknowledges that:
•
should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any
action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the
disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please contact Karen E. Anderson of Cooley LLP at (858) 550-6088.
Sincerely,
TOCAGEN INC.
By:
/s/ Mark Foletta
Mark Foletta
Chief Financial Officer